Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 7/20 | 0.34 |
| ▸ | ESR1 | P03372 | 5/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 2/20 | 0.31 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.31 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6574631 | 0.86 | ESR2 (0.39) | ESR2ESR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL43455 | 0.81 | ESR2 (0.47) | ESR2ESR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL27607674 | 0.80 | AKR1C3 (0.44) | AKR1C3AKR1C1 | |
| SCHEMBL27685209 | 0.78 | AKR1C3 (0.47) | AKR1C3AKR1C1 | |
| SCHEMBL10935897 | 0.77 | POLB (0.38) | ESR2ESR1CYP3A4CYP2C9 | |
| SCHEMBL15255159 | 0.77 | ESR2 (0.37) | ESR2ESR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL27992339 | 0.77 | CNR2 (0.51) | ESR2ESR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL21538 | 0.77 | ESR2 (0.42) | ESR2ESR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL22833 | 0.74 | CYP11B2 (0.42) | ESR2ESR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5543159 | 0.74 | CYP11B2 (0.42) | ESR2ESR1CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2001091796-A2 | METHODS, COMPOUNDS AND COMPOSITIONS FOR TREATING GOUT | GUILFORD PHARMACEUTICALS INC. (US) | 2001-12-06 | — | — | WO | disclosed |